Trypanosoma cruzi: Inhibition by spirogermanium hydrochloride

Herbert B. Tanowitz, Debra J. Brennessel, Stephen G. Baum, Miklos P. Salgo, Vicki Braunstein, Murray Wittner

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Spirogermanium is an antineoplastic agent that has been shown to be useful for the treatment of a variety of solid tumors and Plasmodium falciparum infection. We found that this agent, at concentrations of 1-10 μg/ml, markedly inhibited the growth of epimastigotes of Trypanosoma cruzi. This inhibition of growth was seen in liver infusion tryptose cultures as well as on agar where colonial growth was inhibited markedly. Ultrastructural studies demonstrated that affected organisms were round and swollen and contained vacuoles, lamellar structures, and multivesicular bodies. Spirogermanium also significantly decreased the growth of intracellular amastigotes in myotubes. Pretreatment of myotubes with the agent protected them from infection with trypomastigotes but tachyzoites of Toxoplasma sp. readily infected pretreated cells. These data suggest that spirogermanium may be useful as a chemotherapeutic agent against T. cruzi.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalExperimental Parasitology
Volume64
Issue number1
DOIs
StatePublished - 1987

Fingerprint

spirogermanium
Trypanosoma cruzi
Skeletal Muscle Fibers
Growth
Multivesicular Bodies
Toxoplasma
Plasmodium falciparum
Vacuoles
Antineoplastic Agents
Malaria
Agar
Liver
Infection

Keywords

  • Chemotherapeutic agent
  • Chemotherapy
  • Hemoflagellate
  • Muscle cells
  • Protozoa, parasitic
  • Spirogermanium hydrochloride
  • Trypanosoma cruzi

ASJC Scopus subject areas

  • Immunology
  • Parasitology
  • Infectious Diseases

Cite this

Tanowitz, H. B., Brennessel, D. J., Baum, S. G., Salgo, M. P., Braunstein, V., & Wittner, M. (1987). Trypanosoma cruzi: Inhibition by spirogermanium hydrochloride. Experimental Parasitology, 64(1), 57-63. https://doi.org/10.1016/0014-4894(87)90008-7

Trypanosoma cruzi : Inhibition by spirogermanium hydrochloride. / Tanowitz, Herbert B.; Brennessel, Debra J.; Baum, Stephen G.; Salgo, Miklos P.; Braunstein, Vicki; Wittner, Murray.

In: Experimental Parasitology, Vol. 64, No. 1, 1987, p. 57-63.

Research output: Contribution to journalArticle

Tanowitz, HB, Brennessel, DJ, Baum, SG, Salgo, MP, Braunstein, V & Wittner, M 1987, 'Trypanosoma cruzi: Inhibition by spirogermanium hydrochloride', Experimental Parasitology, vol. 64, no. 1, pp. 57-63. https://doi.org/10.1016/0014-4894(87)90008-7
Tanowitz, Herbert B. ; Brennessel, Debra J. ; Baum, Stephen G. ; Salgo, Miklos P. ; Braunstein, Vicki ; Wittner, Murray. / Trypanosoma cruzi : Inhibition by spirogermanium hydrochloride. In: Experimental Parasitology. 1987 ; Vol. 64, No. 1. pp. 57-63.
@article{e8e9c1000e234bc29e485e04235827bf,
title = "Trypanosoma cruzi: Inhibition by spirogermanium hydrochloride",
abstract = "Spirogermanium is an antineoplastic agent that has been shown to be useful for the treatment of a variety of solid tumors and Plasmodium falciparum infection. We found that this agent, at concentrations of 1-10 μg/ml, markedly inhibited the growth of epimastigotes of Trypanosoma cruzi. This inhibition of growth was seen in liver infusion tryptose cultures as well as on agar where colonial growth was inhibited markedly. Ultrastructural studies demonstrated that affected organisms were round and swollen and contained vacuoles, lamellar structures, and multivesicular bodies. Spirogermanium also significantly decreased the growth of intracellular amastigotes in myotubes. Pretreatment of myotubes with the agent protected them from infection with trypomastigotes but tachyzoites of Toxoplasma sp. readily infected pretreated cells. These data suggest that spirogermanium may be useful as a chemotherapeutic agent against T. cruzi.",
keywords = "Chemotherapeutic agent, Chemotherapy, Hemoflagellate, Muscle cells, Protozoa, parasitic, Spirogermanium hydrochloride, Trypanosoma cruzi",
author = "Tanowitz, {Herbert B.} and Brennessel, {Debra J.} and Baum, {Stephen G.} and Salgo, {Miklos P.} and Vicki Braunstein and Murray Wittner",
year = "1987",
doi = "10.1016/0014-4894(87)90008-7",
language = "English (US)",
volume = "64",
pages = "57--63",
journal = "Experimental Parasitology",
issn = "0014-4894",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Trypanosoma cruzi

T2 - Inhibition by spirogermanium hydrochloride

AU - Tanowitz, Herbert B.

AU - Brennessel, Debra J.

AU - Baum, Stephen G.

AU - Salgo, Miklos P.

AU - Braunstein, Vicki

AU - Wittner, Murray

PY - 1987

Y1 - 1987

N2 - Spirogermanium is an antineoplastic agent that has been shown to be useful for the treatment of a variety of solid tumors and Plasmodium falciparum infection. We found that this agent, at concentrations of 1-10 μg/ml, markedly inhibited the growth of epimastigotes of Trypanosoma cruzi. This inhibition of growth was seen in liver infusion tryptose cultures as well as on agar where colonial growth was inhibited markedly. Ultrastructural studies demonstrated that affected organisms were round and swollen and contained vacuoles, lamellar structures, and multivesicular bodies. Spirogermanium also significantly decreased the growth of intracellular amastigotes in myotubes. Pretreatment of myotubes with the agent protected them from infection with trypomastigotes but tachyzoites of Toxoplasma sp. readily infected pretreated cells. These data suggest that spirogermanium may be useful as a chemotherapeutic agent against T. cruzi.

AB - Spirogermanium is an antineoplastic agent that has been shown to be useful for the treatment of a variety of solid tumors and Plasmodium falciparum infection. We found that this agent, at concentrations of 1-10 μg/ml, markedly inhibited the growth of epimastigotes of Trypanosoma cruzi. This inhibition of growth was seen in liver infusion tryptose cultures as well as on agar where colonial growth was inhibited markedly. Ultrastructural studies demonstrated that affected organisms were round and swollen and contained vacuoles, lamellar structures, and multivesicular bodies. Spirogermanium also significantly decreased the growth of intracellular amastigotes in myotubes. Pretreatment of myotubes with the agent protected them from infection with trypomastigotes but tachyzoites of Toxoplasma sp. readily infected pretreated cells. These data suggest that spirogermanium may be useful as a chemotherapeutic agent against T. cruzi.

KW - Chemotherapeutic agent

KW - Chemotherapy

KW - Hemoflagellate

KW - Muscle cells

KW - Protozoa, parasitic

KW - Spirogermanium hydrochloride

KW - Trypanosoma cruzi

UR - http://www.scopus.com/inward/record.url?scp=0023258089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023258089&partnerID=8YFLogxK

U2 - 10.1016/0014-4894(87)90008-7

DO - 10.1016/0014-4894(87)90008-7

M3 - Article

C2 - 3301388

AN - SCOPUS:0023258089

VL - 64

SP - 57

EP - 63

JO - Experimental Parasitology

JF - Experimental Parasitology

SN - 0014-4894

IS - 1

ER -